Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says

MT Newswires Live

2025/12/11

Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.

Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.

Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products "multi-billion-dollar opportunities."

The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.

Price: 19.59, Change: +1.15, Percent Change: +6.21

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590534392"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590534392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590534392?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590534392","market":"sh","top_or_hot":-1,"title":"Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-11 01:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DYN","symbol_name":"戴纳基","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590534392","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590534392","pubTimestamp":1765388276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DYN":"戴纳基","RNA":"Avidity Biosciences, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","OPY":"奥本海默控股","BK4127":"投资银行业与经纪业","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"奥本海默表示，Dyne Therapeutics最大的催化剂是Avidity Biosciences 2026年下半年的DM1读数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1.5,"OPY":1.5,"DYN":1.5},"content_text":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.Price: 19.59, Change: +1.15, Percent Change: +6.21","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}